advertisement
Heah T 20
Showing records 1 to 20 | Display only abstracts from Heah T in IGR 21-494676 Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study
Sit AJ; Gupta D; Kazemi A; McKee H; Challa P; Liu KC; Lopez J; Kopczynski C; Heah T
American Journal of Ophthalmology 2021; 226: 262-269 (IGR: 22-2)
90997 Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension
Singh IP; Fechtner RD; Myers JS; Kim T; Usner DW; McKee H; Sheng H; Lewis RA; Heah T; Kopczynski CC
Journal of Glaucoma 2020; 29: 878-884 (IGR: 21-4)
86422 Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2
Asrani S; Bacharach J; Holland E; McKee H; Sheng H; Lewis RA; Kopczynski CC; Heah T
Advances in Therapy 2020; 37: 1620-1631 (IGR: 21-2)
85019 Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2
Wisely CE; Sheng H; Heah T; Kim T
Advances in Therapy 2020; 37: 1114-1123 (IGR: 21-1)
80619 Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study
Khouri AS
American Journal of Ophthalmology 2019; 204: 97-104 (IGR: 20-3)
81324 Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: 3-Month Data From a Randomized Phase 3 Trial
Asrani S; Robin AL
American Journal of Ophthalmology 2019; 207: 248-257 (IGR: 20-3)
80619 Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study
Serle JB
American Journal of Ophthalmology 2019; 204: 97-104 (IGR: 20-3)
81324 Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: 3-Month Data From a Randomized Phase 3 Trial
Serle JB
American Journal of Ophthalmology 2019; 207: 248-257 (IGR: 20-3)
80619 Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study
Bacharach J; Usner DW
American Journal of Ophthalmology 2019; 204: 97-104 (IGR: 20-3)
81324 Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: 3-Month Data From a Randomized Phase 3 Trial
Lewis RA
American Journal of Ophthalmology 2019; 207: 248-257 (IGR: 20-3)
80619 Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study
Lewis RA
American Journal of Ophthalmology 2019; 204: 97-104 (IGR: 20-3)
81324 Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: 3-Month Data From a Randomized Phase 3 Trial
Usner DW
American Journal of Ophthalmology 2019; 207: 248-257 (IGR: 20-3)
80619 Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study
Braswell P
American Journal of Ophthalmology 2019; 204: 97-104 (IGR: 20-3)
81324 Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: 3-Month Data From a Randomized Phase 3 Trial
Kopczynski CC; Heah T
American Journal of Ophthalmology 2019; 207: 248-257 (IGR: 20-3)
80619 Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study
Kopczynski CC
American Journal of Ophthalmology 2019; 204: 97-104 (IGR: 20-3)
81324 Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: 3-Month Data From a Randomized Phase 3 Trial
American Journal of Ophthalmology 2019; 207: 248-257 (IGR: 20-3)
80619 Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study
Heah T;
American Journal of Ophthalmology 2019; 204: 97-104 (IGR: 20-3)
79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Kahook MY; Serle JB; Mah FS; Kim T; Raizman MB; Heah T; Ramirez-Davis N; Kopczynski CC; Usner DW; Novack GD;
American Journal of Ophthalmology 2019; 200: 130-137 (IGR: 20-2)
78293 Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension
Kopczynski CC; Heah T
Drugs of Today 2018; 54: 467-478 (IGR: 19-4)
75444 Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)
Serle JB; Katz LJ; McLaurin E; Heah T; Ramirez-Davis N; Usner DW; Novack GD; Kopczynski CC;
American Journal of Ophthalmology 2018; 186: 116-127 (IGR: 19-2)
